RxSight reported third-quarter 2026 total revenue of $24.6 million, down 19% from the prior-year period, driven by 23,128 Light Adjustable Lens units sold. The company posted a net loss of $(16.2) million, or $(0.39) per share, compared to a loss of $(9.8) million in the year-ago quarter. Gross margin declined to 73.6% from 79.9%, primarily due to increased inventory reserves and higher costs for LAL and LDD products. Cash, cash equivalents, and short-term investments totaled $254.7 million as of September 30, 2026. RxSight is an ophthalmic medical device company dedicated to providing customized vision solutions following cataract surgery.
